Literature DB >> 23769501

Comparative effectiveness of surfactant preparations in premature infants.

Andrea Trembath1, Christoph P Hornik, Reese Clark, P Brian Smith, Julie Daniels, Matthew Laughon.   

Abstract

OBJECTIVE: To compare effectiveness of 3 surfactant preparations (beractant, calfactant, and poractant alfa) in premature infants for preventing 3 outcomes: (1) air leak syndromes; (2) death; and (3) bronchopulmonary dysplasia (BPD) or death (composite outcome). STUDY
DESIGN: We conducted a comparative effectiveness study of premature infants admitted to 322 neonatal intensive care units in the US from 2005-2010 who were treated with beractant, calfactant, or poractant alfa. We compared the incidence of air leak syndromes, death, and BPD or death, adjusting for gestational age (GA), antenatal steroids, discharge year, and small for GA status.
RESULTS: A total of 51282 infants received surfactant; 40% received beractant, 30% calfactant, and 30% poractant alfa. Median birth weight was 1435 g (IQR 966-2065); median GA was 30 weeks (27-33). On adjusted analysis, we observed a similar risk of air leak syndromes (calfactant vs beractant OR = 1.17 [95% CI: 0.95, 1.43]; calfactant vs poractant OR = 1.23 [0.98, 1.56]; beractant vs poractant OR = 1.06 [0.87, 1.29]), death (calfactant vs beractant OR = 1.14 [0.93, 1.39]; calfactant vs poractant OR = 0.98 [0.78, 1.23]; beractant vs poractant OR = 0.86 [0.72, 1.04]), and BPD or death (calfactant vs beractant OR = 1.08 [0.93, 1.26]; calfactant vs poractant OR = 1.19 [1.00, 1.41]; beractant vs poractant OR = 1.10 [0.96, 1.27]).
CONCLUSIONS: Beractant, calfactant, and poractant alfa demonstrated similar effectiveness in prevention of air leak syndromes, death, and BPD or death in premature infants when adjusted for site. Previously described differences in mortality between surfactants likely do not represent true differences in effectiveness but may relate to site variation in outcomes.
Copyright © 2013 Mosby, Inc. All rights reserved.

Entities:  

Keywords:  BPD; Bronchopulmonary dysplasia; GA; Gestational age; NICU; Neonatal intensive care unit; RDS; Respiratory distress syndrome

Mesh:

Substances:

Year:  2013        PMID: 23769501      PMCID: PMC3779477          DOI: 10.1016/j.jpeds.2013.04.053

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  25 in total

1.  Comparison of Infasurf (calf lung surfactant extract) to Survanta (Beractant) in the treatment and prevention of respiratory distress syndrome.

Authors:  B T Bloom; J Kattwinkel; R T Hall; P M Delmore; E A Egan; J R Trout; M H Malloy; D R Brown; I R Holzman; C H Coghill; W A Carlo; A K Pramanik; M A McCaffree; P L Toubas; S Laudert; L L Gratny; K B Weatherstone; J H Seguin; L D Willett; G R Gutcher; D H Mueller; W H Topper
Journal:  Pediatrics       Date:  1997-07       Impact factor: 7.124

2.  A multicenter randomized masked comparison trial of synthetic surfactant versus calf lung surfactant extract in the prevention of neonatal respiratory distress syndrome.

Authors:  M L Hudak; D J Martin; E A Egan; E J Matteson; N J Cummings; A L Jung; L V Kimberlin; R L Auten; A A Rosenberg; J M Asselin; M R Belcastro; P K Donohue; C R Hamm; R D Jansen; A S Brody; M M Riddlesberger; P Montgomery
Journal:  Pediatrics       Date:  1997-07       Impact factor: 7.124

3.  Effects of surfactant therapy on outcome of infants with birth weights of 600 to 750 grams.

Authors:  T B Ferrara; R E Hoekstra; R J Couser; J C Jackson; C L Anderson; T F Myers; J R Raye
Journal:  J Pediatr       Date:  1991-09       Impact factor: 4.406

4.  Response to Dr Egan's letter.

Authors:  R Ramanathan; J J Bhatia; K Sekar; F R Ernst
Journal:  J Perinatol       Date:  2013-02       Impact factor: 2.521

5.  A comparison of surfactant as immediate prophylaxis and as rescue therapy in newborns of less than 30 weeks' gestation.

Authors:  J W Kendig; R H Notter; C Cox; L J Reubens; J M Davis; W M Maniscalco; R A Sinkin; A Bartoletti; H S Dweck; M J Horgan
Journal:  N Engl J Med       Date:  1991-03-28       Impact factor: 91.245

6.  A European multicenter randomized controlled trial of single dose surfactant therapy for idiopathic respiratory distress syndrome.

Authors:  J D Horbar; R F Soll; H Schachinger; G Kewitz; H T Versmold; W Lindner; G Duc; D Mieth; O Linderkamp; E P Zilow
Journal:  Eur J Pediatr       Date:  1990-03       Impact factor: 3.183

7.  A cluster-randomized trial of benchmarking and multimodal quality improvement to improve rates of survival free of bronchopulmonary dysplasia for infants with birth weights of less than 1250 grams.

Authors:  Michele Walsh; Abbott Laptook; S Nadya Kazzi; William A Engle; Qing Yao; Maynard Rasmussen; Susie Buchter; Gregory Heldt; William Rhine; Rose Higgins; Kenneth Poole
Journal:  Pediatrics       Date:  2007-05       Impact factor: 7.124

8.  Comparison of Infasurf (calfactant) and Survanta (beractant) in the prevention and treatment of respiratory distress syndrome.

Authors:  Barry T Bloom; Reese H Clark
Journal:  Pediatrics       Date:  2005-08       Impact factor: 7.124

9.  Trends in mortality and morbidity for very low birth weight infants, 1991-1999.

Authors:  Jeffrey D Horbar; Gary J Badger; Joseph H Carpenter; Avroy A Fanaroff; Sarah Kilpatrick; Meena LaCorte; Roderic Phibbs; Roger F Soll
Journal:  Pediatrics       Date:  2002-07       Impact factor: 7.124

10.  Randomised clinical trial of two treatment regimens of natural surfactant preparations in neonatal respiratory distress syndrome.

Authors:  C P Speer; O Gefeller; P Groneck; E Laufkötter; C Roll; L Hanssler; K Harms; E Herting; H Boenisch; J Windeler
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  1995-01       Impact factor: 5.747

View more
  30 in total

Review 1.  The role of surfactant and non-invasive mechanical ventilation in early management of respiratory distress syndrome in premature infants.

Authors:  Narayan Prabhu Iyer; Maroun Jean Mhanna
Journal:  World J Pediatr       Date:  2014-08-15       Impact factor: 2.764

2.  Poractant Alfa Versus Beractant for Neonatal Respiratory Distress Syndrome: A Retrospective Cost Analysis.

Authors:  Sara Brown; Jeff Hurren; Heidi Sartori
Journal:  J Pediatr Pharmacol Ther       Date:  2018 Sep-Oct

Review 3.  Evolution of surfactant therapy for respiratory distress syndrome: past, present, and future.

Authors:  Smeeta Sardesai; Manoj Biniwale; Fiona Wertheimer; Arlene Garingo; Rangasamy Ramanathan
Journal:  Pediatr Res       Date:  2016-10-05       Impact factor: 3.756

4.  Association of Early Inhaled Nitric Oxide With the Survival of Preterm Neonates With Pulmonary Hypoplasia.

Authors:  Kevin R Ellsworth; Marc A Ellsworth; Amy L Weaver; Kristin C Mara; Reese H Clark; William A Carey
Journal:  JAMA Pediatr       Date:  2018-07-02       Impact factor: 16.193

5.  Creation of a Multicenter Pediatric Inpatient Data Repository Derived from Electronic Health Records.

Authors:  Christoph P Hornik; Andrew M Atz; Catherine Bendel; Francis Chan; Kevin Downes; Robert Grundmeier; Ben Fogel; Debbie Gipson; Matthew Laughon; Michael Miller; Michael Smith; Chad Livingston; Cindy Kluchar; Anne Heath; Chanda Jarrett; Brian McKerlie; Hetalkumar Patel; Christina Hunter
Journal:  Appl Clin Inform       Date:  2019-05-08       Impact factor: 2.342

6.  Comparison of the Pharmacoeconomics of Calfactant and Poractant Alfa in Surfactant Replacement erapy.

Authors:  Michael M Zayek; Fabien G Eyal; Robert C Smith
Journal:  J Pediatr Pharmacol Ther       Date:  2018 Mar-Apr

7.  Pharmacoepidemiology of Furosemide in the Neonatal Intensive Care Unit.

Authors:  Elizabeth J Thompson; Daniel K Benjamin; Rachel G Greenberg; Karan R Kumar; Kanecia O Zimmerman; Matthew Laughon; Reese H Clark; P Brian Smith; Christoph P Hornik
Journal:  Neonatology       Date:  2020-10-07       Impact factor: 4.035

8.  Association of Adverse Hearing, Growth, and Discharge Age Outcomes With Postnatal Cytomegalovirus Infection in Infants With Very Low Birth Weight.

Authors:  Kristin E D Weimer; Matthew S Kelly; Sallie R Permar; Reese H Clark; Rachel G Greenberg
Journal:  JAMA Pediatr       Date:  2020-02-01       Impact factor: 16.193

9.  Evaluation of Gentamicin Exposure in the Neonatal Intensive Care Unit and Hearing Function at Discharge.

Authors:  Mihai Puia-Dumitrescu; Olivia M Bretzius; Nia Brown; James A Fitz-Henley; Rebecca Ssengonzi; Caroline S Wechsler; Keyaria D Gray; Daniel K Benjamin; P Brian Smith; Reese H Clark; Daniel Gonzalez; Christoph P Hornik
Journal:  J Pediatr       Date:  2018-09-21       Impact factor: 4.406

10.  Outcomes associated with surfactant in more mature and larger premature infants with respiratory distress syndrome.

Authors:  Wesley Jackson; Genevieve Taylor; Nicolas A Bamat; Kanecia Zimmerman; Reese Clark; Daniel K Benjamin; Matthew M Laughon; Rachel G Greenberg; Christoph P Hornik
Journal:  J Perinatol       Date:  2020-02-20       Impact factor: 2.521

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.